Jarden Sticks to Their Hold Rating for Centuria Capital Group (CNI)
Confident Investing Starts Here:
Pirenc covers the Real Estate sector, focusing on stocks such as Home Consortium Ltd, Charter Hall Group, and Goodman Group. According to TipRanks, Pirenc has an average return of 4.7% and a 60.10% success rate on recommended stocks.
Currently, the analyst consensus on Centuria Capital Group is a Hold with an average price target of A$1.76.
Based on Centuria Capital Group's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$229.42 million and a GAAP net loss of A$518 thousand. In comparison, last year the company earned a revenue of A$136.06 million and had a net profit of A$45.21 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Piper Sandler Says These 2 Stocks Are Top Picks for the Second Half of 2025
There's no magic formula for picking winning stocks, but having the right guide can make all the difference. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That's where Wall Street's analysts come in. With a front-row seat to market movements and company performance, these pros make it their business to spot standout opportunities. And now, with 2025 beyond the halfway mark, it's the perfect moment to check in on the names they're backing for the rest of the year. Watching the current mid-year situation for Piper Sandler, analyst Jason Bednar lays out the attributes he's looking for in top-pick stocks, writing: 'Key themes across our top names include confidence we have in management's execution against guidance and Street estimates for the coming quarters, balance sheet flexibility that is good and/or improving, and risk/reward that skews favorably based on a combination of catalysts and valuation on shares.' With this in mind, we dug into the TipRanks database to get the broader Wall Street take on two of his top picks, and both are rated Buy, with the potential for double-digit gains. Let's break down the names, the numbers, and what makes them stand out. STERIS (STE) First up on our list, STERIS, is a medical technology (medtech) company. STERIS was founded in 1985 and is based in Ohio; the company got its start specializing in low-temperature liquid sterilization of surgical instruments. Today, the company is a global leader in infection prevention, offering a line of products and services designed to support patient care for a better medical outcome. To achieve that goal, STERIS offers a diverse array of products, including medical consumables such as detergents, endoscopy accessories, and barrier devices. On the service side, the company can install and maintain medical equipment, provide sterilization for medical devices, repair medical instruments and scopes, and provide lab testing. Finally, STERIS can also provide its customers with larger-scale capital equipment, such as surgical tables, automated endoscope reprocessors, and even integrated connectivity solutions for today's high-tech operating rooms. STERIS offers its products under several categories, and reports its revenue under the categories Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The largest of these is Healthcare, which accounted for approximately 73% of the company's total revenue in its last reported quarter. That quarter was fiscal 4Q25 (March quarter), for which STERIS reported $1.5 billion in total revenue. This was up 4% year-over-year and beat the forecast by $30 million. At the bottom line, STERIS realized a quarterly adjusted net income of $2.74 per diluted share, a figure that was 14 cents above expectations. The company's free cash flow rose year-over-year, from $620.3 million to $787.2 million in the current report. Checking in with Piper Sandler, we find that analyst Bednar wastes no time in explaining why this stock made his list. Bednar writes, 'Why is it a top idea? STE is a model of consistency, posting MSD+ top-line and HSD/LDD bottom-line growth in six of the past seven years, underpinned by healthy end markets, disciplined capital allocation and a focus on lean operations. For medtech investors, that's a model deserving of a premium valuation. Growth in the high-margin AST segment has improved sequentially for six consecutive quarters, and the segment growth outlook has gotten cleaner of late… Balance sheet leverage is as light as it's been in several years (~1.3x net leverage), and this Board/mgmt team have a bias to accretive M&A.' Based on this stance, Bednar rates STE shares as Overweight (i.e., Buy), with a $280 price target to suggest a one-year upside potential of 24%. (To watch Bednar's track record, click here) The consensus rating here is a Moderate Buy, based on 5 Buy and 2 Hold ratings. Meanwhile, the $270.33 average target price indicates room for an upside of 20% by this time next year. (See STE stock forecast) Merit Medical Systems (MMSI) The second stock we're looking at here is another medtech, Merit Medical Systems. This firm, based in the suburbs of Salt Lake City, Utah, is known as a developer, manufacturer, and distributor of medical devices, particularly devices used in interventional, diagnostic, and therapeutic procedures. Merit Medical's product lines feature proprietary designs, and are intended to be disposable; they are most often used in the fields of cardiology, radiology, oncology, critical care, and endoscopy. Merit Medical has a global footprint, with some 7,300 employees, including an international team of marketers and clinical support that totals more than 800. The company is recognized as a global leader in disposable medical tools. The company boasts a market cap of $5 billion. Earlier this month, Merit suffered a sharp blow to its stock price, falling as much as 10% on July 16, after a regulatory disclosure. That disclosure involved a warning letter from the FDA, regarding issues of quality control at one of the company's manufacturing facilities. These types of warnings are not uncommon from regulators, but in this case, the timing is a problem – Merit is currently expanding its product lines, and a warning letter of this type may have a stronger impact than usual. The company has already stated that it is working in concert with the FDA to address the issues raised in the letter. Looking at Merit's product lines, we find that the company has its hands in a wide range of categories. To give a small list: the company produces hemostasis accessories, dialysis equipment, safety kits, infusion systems, pulmonary stents, GI dilation balloons, and blood sampling devices. The company also provides educational resources, including on-demand courses and recorded webinars, to provide tutorials on its various equipment lines and products. We can also note that on May 6 this year, Merit announced its latest regulatory approval, with Health Canada's approval of Merit's Wrapsody Cell-Impermeable Endoprosthesis. The company is also undergoing a leadership change, and current CEO Fred Lampropoulos will be stepping down in October. His place will be taken by Martha Aronson, effective on October 3. Mr. Lampropoulos will remain as Chairman of the Board. Merit's last quarterly report covered 1Q25, and in that quarter the company had revenues of $355.4 million. This was up 10% year-over-year and beat the forecast by $2.8 million. The non-GAAP EPS figure, of 86 cents, beat expectations by 11 cents per share. Checking in again with Piper Sandler's Bednar, we see the analyst weighing various pros and cons here, writing, 'MMSI has demonstrated durable and consistent growth and management has been superb in managing investor expectations over the past 4+ years… Management already positively pre-announced 2Q and detailed CEO transitions plans, but we also see an EPS beat and guidance raise as being in order. The WRAPSODY reimbursement strategy will be a focal point after failing to secure TPT on management's previously announced timeline, but we're optimistic the developments to date will result in this being more of a short delay for securing TPT.' Summing up, Bednar sees this medtech as a solid choice, and advises investors to buy in, saying of MMSI, 'Longer-term, we believe an extension of what's been a solid execution story should keep MMSI one of the premium mid-cap assets in medtech.' These comments are complemented by an Overweight (i.e., Buy) rating, and a price target which, at $110, points toward a one-year gain of 29%. This stock has earned a Strong Buy from the Street's analysts, a consensus based on 10 recent reviews that split 9 to 1 in favor of Buy over Hold. The shares are currently trading for $85.06 and the average price target of $108.80 implies the stock will gain 28% in the next 12 months. (See MMSI stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Business Insider
12 hours ago
- Business Insider
Ford Stock (NYSE:F) Slips as Ford Bronco Sport Raptor Breaks Cover
Legacy automaker Ford (F) has been trading on the back of its 'no boring cars' philosophy for a while now, and given what we have seen so far, it may be able to continue doing so for some time to come. In fact, the Ford Bronco Sport Raptor was recently spotted in the wild, looking anything but boring. Investors, though, were a bit less sure. They sent Ford shares sliding fractionally down in Thursday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The Ford Bronco line has already seen one refresh, reports noted, with the 2025 model year. That was noteworthy in and of itself as the vehicle only saw its debut in 2021. But now, a new version is said to be coming soon, along with some minor tweaks. This new version is the Ford Bronco Sport Raptor, and reports have already spotted it out in the wild. The biggest reason that anyone could tell this was a Sport Raptor is that the new vehicle has Raptor badges on the front doors, as well as one on the rear tailgate. There are also some cosmetic improvements like a taller ride height as well as larger fender flares. The increased ride height is actually important for one other upgrade: a new set of BFGoodrich Mud-Terrain T/A KM3 tires. These tires, reports note, are more commonly used with off-roading in mind, particularly on rocky or muddy terrain. Earnings Season Approaches With Ford set to reveal its earnings report in just six days, some are wondering if Ford's earnings report will give the stock price a lift. With earnings expected to be down against last year's figures—analysts expect $0.33 per share against the $0.47 per share seen this time last year—and revenues also expected to take a roughly 2% hit, some wonder if Ford's share price can get any kind of lift. Sadly, with numbers like those already expected, it would take a fairly big surprise to turn anything around in the short term. And while there are some signs of life from discretionary income in the consumer space, it may not be enough to give any real boost in the short term. Is Ford Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Hold consensus rating on F stock based on two Buys, 12 Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 1.97% rally in its share price over the past year, the average F price target of $10.14 per share implies 10.23% downside risk.
Business Insider
13 hours ago
- Business Insider
Lynas Rare Earths (LYSCF) Receives a Sell from Macquarie
Macquarie analyst maintained a Sell rating on Lynas Rare Earths today and set a price target of A$9.00. The company's shares closed yesterday at $7.19. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Macquarie, Lynas Rare Earths also received a Sell from Ord Minnett's Matthew Hope in a report issued today. However, on the same day, Morgan Stanley maintained a Buy rating on Lynas Rare Earths (Other OTC: LYSCF).
